Last update 24 May 2024

Relmacabtagene autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Carteyva, CD19-directed Chimeric Antigen Recepter T Cells, relma-cel
+ [6]
Target
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (CN), Breakthrough Therapy (CN), Special Review Project (CN)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Follicular Lymphoma
CN
30 Sep 2022
Diffuse Large B-Cell Lymphoma
CN
01 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma recurrentNDA/BLA
CN
04 Jan 2024
Mantle cell lymphoma recurrentNDA/BLA
CN
04 Jan 2024
Mantle cell lymphoma refractoryNDA/BLA
CN
04 Jan 2024
Mantle cell lymphoma refractoryNDA/BLA
CN
04 Jan 2024
Large B-cell lymphomaPhase 3
CN
30 Jan 2022
Systemic Lupus ErythematosusPhase 2
CN
25 Dec 2023
Scleroderma, SystemicPhase 1
CN
01 Jun 2024
Small Lymphocytic LymphomaPhase 1
CN
20 Jun 2022
Recurrent B Acute Lymphoblastic LeukemiaPhase 1
CN
11 May 2022
Refractory B Acute Lymphoblastic LeukemiaPhase 1
CN
11 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
6
vdbwwqslyc(qtgfmlixgx) = The most common TEAE were cytopenias (6/6) and CRS (6/6). with none of ≥ grade 3 CRS. 2 patients experienced neurotoxicity (NT), with 1 of grade 4 NT. ymnmqpskzt (xmybljkcpr )
Negative
14 May 2024
Not Applicable
59
Carteyva
zrdwkucxsp(uktkfhdgfp) = vgfyivyvbh loyvjrltvd (crgcnzyzld )
Positive
04 Jan 2024
Phase 2
66
cvgsgporfn(dlwwsvwnrz) = hxssmtbwpw gtfmfmennr (rnpswcdkio )
Positive
10 Dec 2023
Phase 1/2
68
lmrcnkalpr(fectszqmwx) = caoocyikju ybepoyzwfm (cfednjyrau, 64.73 - 87.49)
Positive
01 Feb 2023
Phase 3
-
ruupvgkgwo(qskvcefhmx) = vopeqhpyjy udmxbntdjy (jmckmujpyi )
Positive
10 Oct 2022
Phase 1
14
eealkwokvv(inppmwfadu) = othbbrdljt ofmjqownaf (wzfwpohhie, 3.2 - NA)
Positive
02 Jun 2022
Phase 2
59
(Carteyva 100x10^6 CAR+T cells)
qbtolxkmvc(ykzssenhgt) = dhxuvqpsmb xipqsorwfm (hrenwcpzpj )
Positive
02 Jun 2022
Phase 1
23
fxzzomuzmz(xjjyrwfxyl) = ccygbnvtfg vrodyobclb (sujoyxctro )
-
02 Jun 2022
Not Applicable
59
cbdlgzjdal(jsllnditjh) = ldpnmhtglj hjkgwxxihk (htkezbxyxb )
Positive
25 Sep 2021
(liso-cel)
cbdlgzjdal(jsllnditjh) = cqdcscqgyx hjkgwxxihk (htkezbxyxb )
Phase 2
59
dksumixjaa(ixjukhqbtk) = ssuuulgwiq fhmvdaxaaj (lcbppokbhw, 46.6 - 73.0)
Positive
01 Feb 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free